Cingulate (CING) Income from Continuing Operations (2021 - 2026)
Cingulate's (CING) quarterly Income from Continuing Operations came in at 6027828.0 in Q4 2025, up 3.85% YoY from 5804220.32 in Q4 2024, and up 19.74% on a QoQ basis from 7510839.0 in Q3 2025.
Cingulate (CING) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Income from Continuing Operations data on file, last reported at 6027828.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 3.85% year-over-year to 6027828.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 23416249.0 (down 50.45% YoY) and the FY2025 annual result came in at 22149379.0, down 38.28% from the prior year.
- Income from Continuing Operations grew to 6027828.0 in Q4 2025, from 7510839.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1333923.0 in Q1 2021 to a low of 15290048.0 in Q3 2021.
- A 5-year average of 4700914.89 and a median of 3892081.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 79.19% in 2022, down 197.16% in 2022.
- Tracing CING's Income from Continuing Operations over 5 years: stood at 2653725.0 in 2021, then sank by 63.82% to 4347427.0 in 2022, then tumbled by 50.73% to 6552750.0 in 2023, then grew by 4.32% to 6269355.0 in 2024, then grew by 3.85% to 6027828.0 in 2025.
- The last three Income from Continuing Operations figures came in at 6027828.0 (Q4 2025), 7510839.0 (Q3 2025), and 3608227.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | -4.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.64 Mn |
| Dec 31, 2025 | -6.03 Mn |
| Sep 30, 2025 | -7.51 Mn |
| Mar 31, 2025 | -3.61 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Sep 30, 2024 | -3.89 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -2.38 Mn |
| Dec 31, 2023 | -6.55 Mn |
| Sep 30, 2023 | -5.65 Mn |
| Jun 30, 2023 | -5.23 Mn |
| Mar 31, 2023 | -3.78 Mn |
| Dec 31, 2022 | -4.35 Mn |
| Sep 30, 2022 | -3.18 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -2.65 Mn |
| Sep 30, 2021 | -15.29 Mn |
| Jun 30, 2021 | -1.43 Mn |
| Mar 31, 2021 | -1.33 Mn |